Xeris Pharmaceuticals, Inc. announced an exclusive agreement with Clinigen Group plc to manage the supply and distribution of Gvoke outside of the United States where Gvoke is not currently licensed. With Clinigen's global infrastructure and expertise in the distribution of important unlicensed medicines, can enable people with diabetes around the world to access Gvoke.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.33 USD | -1.48% | +3.33% | -0.85% |
May. 30 | Sector Update: Health Care Stocks Higher in Afternoon Trading | MT |
May. 30 | Xeris Biopharma Says Potential Levothyroxine Injection Preferred Over Oral Formulation; Shares Rise | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.85% | 345M | |
+45.82% | 765B | |
-6.16% | 354B | |
+19.86% | 331B | |
+9.32% | 299B | |
+18.86% | 248B | |
-1.92% | 219B | |
+11.05% | 216B | |
+5.90% | 164B | |
-0.73% | 162B |
- Stock Market
- Equities
- XERS Stock
- News Xeris Biopharma Holdings, Inc.
- Xeris Pharmaceuticals Signs Exclusive Agreement with Clinigen to Supply and Distribute Gvoke™ Outside the U.S on Named Patient Basis